CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Nascent Biotech Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Nascent Biotech Inc
631 Us Hwy 1, Suite 407
Phone: (612) 961-5656p:612 961-5656 NORTH PALM BEACH, FL  33408  United States Ticker: NBIONBIO
This company ceased filing statements with the SEC on 4/1/2025.
Business Summary
Nascent Biotech, Inc. is a phase II clinical-stage biopharmaceutical company, which is engaged in developing monoclonal antibodies for the treatment of various types of cancer. The Company focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company's lead candidate, Pritumumab (PTB), is a human monoclonal antibody (Mab) that has progressed to Phase 2 clinical trials for the treatment of Brain Cancer. Pritumumab is a fully natural human IgG antibody that was derived using proprietary technology from a B-cell isolated from a tumor draining lymph node of a patient with cervical cancer. Its other products include CLNH5 and MultiPharm. MultiPharm is a proprietary platform technology that may have additive and synergistic effects not only for cancer therapy but also for diabetes, autoimmunity, and transplantation.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20243/31/2024YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Secretary, Director SeanCarrick 56 7/1/2014 7/1/2014
Chief Financial Officer, Chief Accounting Officer, Director Lowell T.Holden 82 5/1/2014 5/1/2014

Business Names
Business Name
Hebei Jinen (Group) Co., Ltd
Heibei Jin-En Fur Co., Ltd
Jin-En Hotel
5 additional Business Names available in full report.

General Information
Outstanding Shares: 172,217,165 (As of 9/30/2024)
Shareholders: 164
Stock Exchange: OTC
Federal Tax Id: 450612715


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, December 7, 2025